Angiotensin Ii Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 2.5 mg
Reference Brands: Giapreza (USA)
Category:
Critical Care
Angiotensin II is available in Injection
and strengths such as 2.5 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Angiotensin II is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Angiotensin II can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Angiotensin II is a peptide endocrine hormone and a key component of the renin–angiotensin–aldosterone system (RAAS), an essential regulatory system responsible for maintaining blood pressure, vascular tone, and fluid balance. It is derived from angiotensinogen, an alpha-globulin prohormone synthesized primarily in the liver and circulated in plasma. Through a cascade of enzymatic reactions, angiotensin II is formed and acts as a potent vasoconstrictor.
Clinically, angiotensin II increases blood pressure by causing direct vasoconstriction of blood vessels and by stimulating the release of aldosterone from the adrenal cortex. Aldosterone promotes sodium and water retention by the kidneys, further contributing to increased intravascular volume and blood pressure stabilization.
Angiotensin II has received approval from the United States Food and Drug Administration (FDA) for use in adult patients with septic or distributive shock who remain hypotensive despite adequate fluid resuscitation and conventional vasopressor therapy. It is administered intravenously in controlled critical care settings.
Due to its targeted mechanism of action, angiotensin II plays an important role in modern shock management protocols and is utilized by multidisciplinary healthcare teams in intensive care environments to support hemodynamic stability in critically ill patients.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing